Identification of novel HCV deletion mutants in chronic hepatitis C patients

Antiviral Therapy

Volumn 17, Issue 8, 2012, Pages 1551-1561

  Kohno, Tomohiko ^a,b   Tsuge, Masataka ^a,b   Hayes, C Nelson ^a,b   Hatakeyama, Tsuyoshi ^a,b   Ohnishi, Mayu ^a,b   Abe, Hiromi ^a,b   Miki, Daiki ^a,b,c   Hiraga, Nobuhiko ^a,b   Imamura, Michio ^a,b   Takahashi, Shoichi ^a,b   Ochi, Hidenori ^a,b,c   Tanaka, Shinji ^a   Chayama, Kazuaki ^a,b,c  

^a HIROSHIMA UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTRUCTURAL PROTEIN 5A; PEGINTERFERON; RIBAVIRIN; VIRUS PROTEIN; VIRUS RNA;

ADULT; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DELETION MUTANT; DRUG RESPONSE; FEMALE; GENE AMPLIFICATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; VIROGENESIS; VIRUS CORE; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION;

AGED; ANTIVIRAL AGENTS; BASE SEQUENCE; DRUG THERAPY, COMBINATION; FEMALE; GENE DELETION; GENE ORDER; GENOME, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84871868615     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2265     Document Type: Article

References (55)

1. Alter HJ, Purcell RH, Shih JW, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989; 321:1494-1500. (Pubitemid 20015539)
2. Cooper S, Erickson AL, Adams EJ, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999; 10:439-449. (Pubitemid 29205480)
3. Lee SH, Kim YK, Kim CS, et al. E2 of hepatitis C virus inhibits apoptosis. J Immunol 2005; 175:8226-8235. (Pubitemid 41798387)
4. Akuta N, Chayama K, Suzuki F, et al. Risk factors of hepatitis C virus-related liver cirrhosis in young adults: positive family history of liver disease and transporter associated with antigen processing 2(TAP2)*0201 allele. J Med Virol 2001; 64:109-116.
5. Dusheiko GM. The natural course of chronic hepatitis C: implications for clinical practice. J Viral Hepat 1998; 5 Suppl 1:9-12.
6. Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol 1998; 28:930-938. (Pubitemid 28275969)
7. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228-1233. (Pubitemid 29181642)
8. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998; 28:1687-1695. (Pubitemid 28549142)
9. Choo QL, Richman KH, Han JH, et al. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991; 88:2451-2455. (Pubitemid 21916435)
10. Friebe P, Bartenschlager R. Genetic analysis of sequences in the 3′ nontranslated region of hepatitis C virus that are important for RNA replication. J Virol 2002; 76:5326-5338. (Pubitemid 34517883)
11. Friebe P, Lohmann V, Krieger N, Bartenschlager R. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. J Virol 2001; 75:12047-12057. (Pubitemid 33115877)
12. Domingo E, Menendez-Arias L, Quinones-Mateu ME, et al. Viral quasispecies and the problem of vaccine-escape and drug-resistant mutants. Prog Drug Res 1997; 48:99-128. (Pubitemid 27242826)
13. Drake JW, Holland JJ. Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 1999; 96:13910-13913.
14. Okamoto H, Kojima M, Okada S, et al. Genetic drift of hepatitis C virus during an 8.2-year infection in a chimpanzee: variability and stability. Virology 1992; 190:894-899.
15. Smith DB, Pathirana S, Davidson F, et al. The origin of hepatitis C virus genotypes. J Gen Virol 1997; 78:321-328. (Pubitemid 27075628)
16. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493-1499. (Pubitemid 28543497)
17. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339:1485-1492. (Pubitemid 28543496)
18. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet 1998; 351:83-87. (Pubitemid 28026633)
19. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol 1997; 26:961-966. (Pubitemid 27242584)
20. Yen YH, Hung CH, Hu TH, et al. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin. Aliment Pharmacol Ther 2008; 27:72-79. (Pubitemid 350212632)
21. Akuta N, Suzuki F, Kawamura Y, et al. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels. J Hepatol 2007; 46:403-410. (Pubitemid 46185701)
22. Akuta N, Suzuki F, Kawamura Y, et al. Prediction of response to pegylated interferon and ribavirin in hepatitis C by polymorphisms in the viral core protein and very early dynamics of viremia. Intervirology 2007; 50:361-368. (Pubitemid 350014920)
23. Kitamura S, Tsuge M, Hatakeyama T, et al. Amino acid substitutions in Core and NS5A region of hepatitis C virus genome can predict the virological reduction with pegylated interferon plus ribavirin therapy. Antivir Ther 2010; 15:1087-1097.
24. Okanoue T, Itoh Y, Hashimoto H, et al. Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. J Gastroenterol 2009; 44:952-963.
25. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
26. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41:1105-1109.
27. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
28. Iwai A, Marusawa H, Takada Y, et al. Identification of novel defective HCV clones in liver transplant recipients with recurrent HCV infection. J Viral Hepat 2006; 13:523-531. (Pubitemid 44100403)
29. Noppornpanth S, Smits SL, Lien TX, Poovorawan Y, Osterhaus AD, Haagmans BL. Characterization of hepatitis C virus deletion mutants circulating in chronically infected patients. J Virol 2007; 81:12496-12503. (Pubitemid 350085863)
30. Yagi S, Mori K, Tanaka E, et al. Identification of novel HCV subgenome replicating persistently in chronic active hepatitis C patients. J Med Virol 2005; 77:399-413. (Pubitemid 41395871)
31. Kumada H, Okanoue T, Onji M, et al. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol Res 2010; 40:8-13.
32. Loguercio C, Di Pierro M, Di Marino MP, et al. Drinking habits of subjects with hepatitis C virus-related chronic liver disease: prevalence and effect on clinical, virological and pathological aspects. Alcohol Alcohol 2000; 35:296-301. (Pubitemid 30433703)
33. Akuta N, Suzuki F, Sezaki H, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. Intervirology 2005; 48:372-380. (Pubitemid 41003622)
34. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87:9524-9528. (Pubitemid 120016475)
35. Abe H, Hayes CN, Ochi H, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54:1094-1101.
36. Lancaster MU, Hodgetts SI, Mackenzie JS, Urosevic N. Characterization of defective viral RNA produced during persistent infection of Vero cells with Murray Valley encephalitis virus. J Virol 1998; 72:2474-2482. (Pubitemid 28100809)
37. Strauss JH, Strauss EG. Evolution of RNA viruses. Annu Rev Microbiol 1988; 42:657-683. (Pubitemid 19179311)
38. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801. (Pubitemid 43261452)
39. Foy E, Li K, Sumpter R, Jr., et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A 2005; 102:2986-2991. (Pubitemid 40299903)
40. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A 2005; 102:2992-2997. (Pubitemid 40299904)
41. Meylan E, Curran J, Hofmann K, et al. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 2005; 437:1167-1172. (Pubitemid 41509355)
42. Oganesyan G, Saha SK, Guo B, et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 2006; 439:208-211. (Pubitemid 43083142)
43. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale M, Jr. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454:523-527.
44. Yoneyama M, Kikuchi M, Natsukawa T, et al. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 2004; 5:730-737. (Pubitemid 39023305)
45. Abe H, Hayes CN, Ochi H, et al. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy. J Hepatol 2011; 54:1094-1101.
46. Abe H, Hayes CN, Ochi H, et al. Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state. J Med Virol 2011; 83:1597-1607.
47. Lohmann V, Korner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110-113. (Pubitemid 29307577)
48. Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791-796. (Pubitemid 41021213)
49. Cheng CP, Pogany J, Nagy PD. Mechanism of DI RNA formation in tombusviruses: dissecting the requirement for primer extension by the tombusvirus RNA dependent RNA polymerase in vitro. Virology 2002; 304:460-473. (Pubitemid 36069184)
50. Lazzarini RA, Keene JD, Schubert M. The origins of defective interfering particles of the negative-strand RNA viruses. Cell 1981; 26:145-154. (Pubitemid 12244494)
51. Kupfermann H, Thiel HJ, Dubovi EJ, Meyers G. Bovine viral diarrhea virus: characterization of a cytopathogenic defective interfering particle with two internal deletions. J Virol 1996; 70:8175-8181. (Pubitemid 26339134)
52. Roux L, Simon AE, Holland JJ. Effects of defective interfering viruses on virus replication and pathogenesis in vitro and in vivo. Adv Virus Res 1991; 40:181-211.
53. Tautz N, Thiel HJ, Dubovi EJ, Meyers G. Pathogenesis of mucosal disease: a cytopathogenic pestivirus generated by an internal deletion. J Virol 1994; 68:3289-3297. (Pubitemid 24129778)
54. Hiramatsu N, Oze T, Yakushijin T, et al. Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin. J Viral Hepat 2009; 16:586-594.
55. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352:1426-1432. (Pubitemid 28510876)